Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.
Identifieur interne : 001894 ( PubMed/Corpus ); précédent : 001893; suivant : 001895Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.
Auteurs : Jesse J. Fryk ; Denese C. Marks ; Jody Hobson-Peters ; Natalie A. Prow ; Daniel Watterson ; Roy A. Hall ; Paul R. Young ; Stefan Reichenberg ; Chryslain Sumian ; Helen M. FaddySource :
- Transfusion [ 1537-2995 ] ; 2016.
English descriptors
- KwdEn :
- Blood Transfusion (methods), Chikungunya virus (drug effects), Chikungunya virus (radiation effects), Dengue Virus (drug effects), Dengue Virus (radiation effects), Humans, Light, Methylene Blue (pharmacology), Plasma (drug effects), Plasma (microbiology), Plasma (radiation effects), Plasma (virology), Virus Inactivation (drug effects), Virus Inactivation (radiation effects).
- MESH :
- chemical , pharmacology : Methylene Blue.
- drug effects : Chikungunya virus, Dengue Virus, Plasma, Virus Inactivation.
- methods : Blood Transfusion.
- microbiology : Plasma.
- radiation effects : Chikungunya virus, Dengue Virus, Plasma, Virus Inactivation.
- virology : Plasma.
- Humans, Light.
Abstract
Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach to manage this transfusion transmission risk, with a number of techniques being used worldwide for the treatment of plasma. In this study, the efficacy of the THERAFLEX MB-Plasma system to inactivate all DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV in plasma, using methylene blue and light illumination at 630 nm, was investigated.
DOI: 10.1111/trf.13729
PubMed: 27456861
Links to Exploration step
pubmed:27456861Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.</title><author><name sortKey="Fryk, Jesse J" sort="Fryk, Jesse J" uniqKey="Fryk J" first="Jesse J" last="Fryk">Jesse J. Fryk</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marks, Denese C" sort="Marks, Denese C" uniqKey="Marks D" first="Denese C" last="Marks">Denese C. Marks</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hobson Peters, Jody" sort="Hobson Peters, Jody" uniqKey="Hobson Peters J" first="Jody" last="Hobson-Peters">Jody Hobson-Peters</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Prow, Natalie A" sort="Prow, Natalie A" uniqKey="Prow N" first="Natalie A" last="Prow">Natalie A. Prow</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Watterson, Daniel" sort="Watterson, Daniel" uniqKey="Watterson D" first="Daniel" last="Watterson">Daniel Watterson</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Hall, Roy A" sort="Hall, Roy A" uniqKey="Hall R" first="Roy A" last="Hall">Roy A. Hall</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Young, Paul R" sort="Young, Paul R" uniqKey="Young P" first="Paul R" last="Young">Paul R. Young</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Reichenberg, Stefan" sort="Reichenberg, Stefan" uniqKey="Reichenberg S" first="Stefan" last="Reichenberg">Stefan Reichenberg</name><affiliation><nlm:affiliation>MacoPharma International GmbH, Langen, Germany; and.</nlm:affiliation></affiliation></author><author><name sortKey="Sumian, Chryslain" sort="Sumian, Chryslain" uniqKey="Sumian C" first="Chryslain" last="Sumian">Chryslain Sumian</name><affiliation><nlm:affiliation>MacoPharma, Mouvaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faddy, Helen M" sort="Faddy, Helen M" uniqKey="Faddy H" first="Helen M" last="Faddy">Helen M. Faddy</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia. hfaddy@redcrossblood.org.au.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27456861</idno><idno type="pmid">27456861</idno><idno type="doi">10.1111/trf.13729</idno><idno type="wicri:Area/PubMed/Corpus">001894</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001894</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.</title><author><name sortKey="Fryk, Jesse J" sort="Fryk, Jesse J" uniqKey="Fryk J" first="Jesse J" last="Fryk">Jesse J. Fryk</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marks, Denese C" sort="Marks, Denese C" uniqKey="Marks D" first="Denese C" last="Marks">Denese C. Marks</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hobson Peters, Jody" sort="Hobson Peters, Jody" uniqKey="Hobson Peters J" first="Jody" last="Hobson-Peters">Jody Hobson-Peters</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Prow, Natalie A" sort="Prow, Natalie A" uniqKey="Prow N" first="Natalie A" last="Prow">Natalie A. Prow</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Watterson, Daniel" sort="Watterson, Daniel" uniqKey="Watterson D" first="Daniel" last="Watterson">Daniel Watterson</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Hall, Roy A" sort="Hall, Roy A" uniqKey="Hall R" first="Roy A" last="Hall">Roy A. Hall</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Young, Paul R" sort="Young, Paul R" uniqKey="Young P" first="Paul R" last="Young">Paul R. Young</name><affiliation><nlm:affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</nlm:affiliation></affiliation></author><author><name sortKey="Reichenberg, Stefan" sort="Reichenberg, Stefan" uniqKey="Reichenberg S" first="Stefan" last="Reichenberg">Stefan Reichenberg</name><affiliation><nlm:affiliation>MacoPharma International GmbH, Langen, Germany; and.</nlm:affiliation></affiliation></author><author><name sortKey="Sumian, Chryslain" sort="Sumian, Chryslain" uniqKey="Sumian C" first="Chryslain" last="Sumian">Chryslain Sumian</name><affiliation><nlm:affiliation>MacoPharma, Mouvaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faddy, Helen M" sort="Faddy, Helen M" uniqKey="Faddy H" first="Helen M" last="Faddy">Helen M. Faddy</name><affiliation><nlm:affiliation>Research and Development, Australian Red Cross Blood Service, Australia. hfaddy@redcrossblood.org.au.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Transfusion</title><idno type="eISSN">1537-2995</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Transfusion (methods)</term><term>Chikungunya virus (drug effects)</term><term>Chikungunya virus (radiation effects)</term><term>Dengue Virus (drug effects)</term><term>Dengue Virus (radiation effects)</term><term>Humans</term><term>Light</term><term>Methylene Blue (pharmacology)</term><term>Plasma (drug effects)</term><term>Plasma (microbiology)</term><term>Plasma (radiation effects)</term><term>Plasma (virology)</term><term>Virus Inactivation (drug effects)</term><term>Virus Inactivation (radiation effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Methylene Blue</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Chikungunya virus</term><term>Dengue Virus</term><term>Plasma</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Blood Transfusion</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Plasma</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Chikungunya virus</term><term>Dengue Virus</term><term>Plasma</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Plasma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Light</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach to manage this transfusion transmission risk, with a number of techniques being used worldwide for the treatment of plasma. In this study, the efficacy of the THERAFLEX MB-Plasma system to inactivate all DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV in plasma, using methylene blue and light illumination at 630 nm, was investigated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27456861</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>14</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-2995</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.</ArticleTitle><Pagination><MedlinePgn>2278-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/trf.13729</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach to manage this transfusion transmission risk, with a number of techniques being used worldwide for the treatment of plasma. In this study, the efficacy of the THERAFLEX MB-Plasma system to inactivate all DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV in plasma, using methylene blue and light illumination at 630 nm, was investigated.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">Pooled plasma units were spiked with DENV-1, DENV-2, DENV-3 DENV-4, or CHIKV and treated with the THERAFLEX MB-Plasma system at four light illumination doses: 20, 40, 60, and 120 (standard dose) J/cm(2) . Pre- and posttreatment samples were collected and viral infectivity was determined. The reduction in viral infectivity was calculated for each dose.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment of plasma with the THERAFLEX MB-Plasma system resulted in at least a 4.46-log reduction in all DENV serotypes and CHIKV infectious virus. The residual infectivity for each was at the detection limit of the assay used at 60 J/cm(2) , with dose dependency also observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrated the THERAFLEX MB-Plasma system can reduce the infectivity of all DENV serotypes and CHIKV spiked into plasma to the detection limit of the assay used at half of the standard illumination dose. This suggests this system has the capacity to be an effective option for managing the risk of DENV or CHIKV transfusion transmission in plasma.</AbstractText><CopyrightInformation>© 2016 AABB.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fryk</LastName><ForeName>Jesse J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Denese C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobson-Peters</LastName><ForeName>Jody</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prow</LastName><ForeName>Natalie A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watterson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Roy A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MacoPharma International GmbH, Langen, Germany; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumian</LastName><ForeName>Chryslain</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MacoPharma, Mouvaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faddy</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Australia. hfaddy@redcrossblood.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Brisbane, Queensland, Australia. hfaddy@redcrossblood.org.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>T42P99266K</RegistryNumber><NameOfSubstance UI="D008751">Methylene Blue</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002646" MajorTopicYN="N">Chikungunya virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008751" MajorTopicYN="N">Methylene Blue</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038301" MajorTopicYN="N">Virus Inactivation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27456861</ArticleId><ArticleId IdType="doi">10.1111/trf.13729</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001894 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001894 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27456861
|texte= Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27456861" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |